NASDAQ:CELUW Celularity (CELUW) Stock Price, News & Analysis → Does this make you sick? (From Allegiance Gold) (Ad) Free CELUW Stock Alerts $0.02 -0.01 (-47.74%) (As of 05/17/2024 08:53 PM ET) Add Compare Share Share Today's Range$0.02▼$0.0350-Day Range$0.02▼$0.0552-Week Range$0.00▼$0.16Volume8,200 shsAverage Volume40,904 shsMarket CapitalizationN/AP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisChartCompetitorsFinancialsOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisChartCompetitorsFinancialsOwnershipSEC FilingsShort InterestSocial Media Get Celularity alerts: Email Address Ad MarketBeatYour $200 account credit is about to expireUpdate to MarketBeat All Access and Save $200 on Your Annual Subscription.Start Your Risk-Free Trial Here About Celularity Stock (NASDAQ:CELUW)Celularity Inc., a clinical-stage biotechnology company, develops off-the-shelf placental-derived allogeneic cell therapies for the treatment of cancer, immune, and infectious diseases. It operates through three segments: Cell Therapy, Degenerative Disease, and BioBanking. The company's lead therapeutic programs include CYCART-19, an allogeneic CAR-T cell for the treatment of non-Hodkin's lymphoma (NHL) and mantle cell lymphoma (MCL); CYNK-001, an allogeneic unmodified natural killer cell that is in Phase I/II clinical trial for the treatment of acute myeloid leukemia (AML); and APPL-001, a genetically modified placental-derived mesenchymal-like adherent stromal cell for the treatment of Crohn's disease. It is also developing CYCART-201 for the treatment of NHL and MCL, and human epidermal growth factor receptor 2 positive cancers; CYNK-301, a next generation chimeric antigen receptor-natural killer (CAR-NK) for treating relapse refractory AML; CYNK-302, a CAR-NK to treat non-small cell lung cancer; and pExo-001, a human postpartum placenta derived exosome product for the treatment of osteoarthritis. It also produces, sells, and licenses products that are used in surgical and wound care markets, such as Biovance, Biovance 3L, Interfyl, and Centaflex; and collects and stores stem cells from umbilical cords and placentas under the LifebankUSA brand. The company has licensing agreement with Sorrento Therapeutics, Inc. for the development and commercialization of licensed CD19 CAR-T products; and research collaboration services agreement with Regeneron Pharmaceuticals, Inc. to support the research of allogeneic cell therapy candidates. The company was founded in 1998 and is based in Florham Park, New Jersey.Read More CELUW Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart CELUW Stock News HeadlinesMay 13, 2024 | americanbankingnews.comCelularity Inc. (NASDAQ:CELUW) Sees Large Growth in Short InterestSee More Headlines Receive CELUW Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Celularity and its competitors with MarketBeat's FREE daily newsletter. Email Address Industry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biotechnology Sub-IndustryN/A Current SymbolNASDAQ:CELUW CUSIPN/A CIK1752828 Webwww.celularity.com Phone908 768 2170FaxN/AEmployees225Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual Sales$14.79 million Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding SharesN/AFree FloatN/AMarket CapN/A OptionableNot Optionable BetaN/A Metaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free Report Key ExecutivesDr. Robert Joseph Hariri M.D. (Age 65)Ph.D., Founder, CEO & Chairman Comp: $1.24MMr. David C. Beers C.F.A. (Age 54)Chief Financial Officer Comp: $455.02kMr. John R. Haines (Age 66)Senior EVP, Global Manager & Chief Administrative Officer Comp: $503.56kRamji KrishnanChief Technology OfficerCarlos RamirezSVP of Investor RelationsMr. Kyle Harold Fletcher Esq. (Age 39)Executive VP, General Counsel & Chief Compliance Officer Dr. Stephen A. Brigido D.P.M. (Age 48)President of Degenerative Diseases Dr. Adrian Kilcoyne M.B.A. (Age 53)M.D., M.P.H., Executive VP, Chief Medical Officer and Head of Global Affairs, Patient Safety & Patient Affairs Sharmila Koppisetti M.D.Senior Vice President of Clinical Dev. Immunology & Drug SafetyMr. Tim WilkSenior Vice President of Technical OperationsMore ExecutivesKey Competitors180 Life SciencesNASDAQ:ATNFW60 Degrees PharmaceuticalsNASDAQ:SXTPWAlpha Tau MedicalNASDAQ:DRTSWApollomicsNASDAQ:APLMWArtelo BiosciencesNASDAQ:ARTLWView All Competitors CELUW Stock Analysis - Frequently Asked Questions How have CELUW shares performed in 2024? Celularity's stock was trading at $0.04 at the start of the year. Since then, CELUW stock has decreased by 62.5% and is now trading at $0.0150. View the best growth stocks for 2024 here. How do I buy shares of Celularity? Shares of CELUW stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:CELUW) was last updated on 5/20/2024 by MarketBeat.com Staff From Our PartnersUrgent Nvidia WarningAltimetryShocking $16T Elon Musk Crypto LeakCrypto 101 MediaHe called Apple at $1.49 and now he says: “Buy these 6 AI stocks.”InvestorPlaceMost important medical advance in 100 yearsThe Oxford ClubCEO of Biggest AI Chipmaker Just Dropped a Bombshell…Banyan Hill PublishingMissed NVDA? Buy this AI stock NOWChaikin AnalyticsForget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THISParadigm PressHe Is Giving Away BitcoinCrypto Swap Profits Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Celularity Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.